profit from every ₹100 of sales.
₹0₹100
Cohance Lifesciences
₹459.80-2.49% today
-14.6% in 1 year
1-year low ₹279.751-year high ₹539.95
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹98.16 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cohance Lifesciences sold, what it kept, and what it did with the cash.
Sales went from ₹13.3 billion in 2023 to ₹22.7 billion in 2026, with ₹1.79 billion of profit last year.
SalesProfit
Cohance Lifesciences vs. similar companies
Cohance Lifesciences grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Cohance Lifesciences | 98.2× · Very expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Cohance Lifesciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 13,311 | 10,341 | 26,085 | 22,686 | |
| 7,449 | 7,162 | 17,920 | 16,059 | |
| 5,263 | 3,544 | 6,303 | 2,397 | |
| 6,205 | 4,672 | 8,505 | 4,316 | |
| 4,113 | 3,003 | 4,873 | 1,792 | |
| 16.16 | 11.80 | 12.68 | 4.68 | |
| 56.0% | 69.3% | 68.7% | 70.8% | |
| 39.5% | 34.3% | 24.2% | 10.6% | |
| 30.9% | 29.0% | 18.7% | 7.9% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 19,657 | 22,549 | 30,318 | 57,296 |
| Cash | 648 | 472 | 854 | 491 |
| Total debt | 703 | 650 | 2,791 | 4,005 |
| Total liabilities | 2,306 | 2,042 | 11,911 | 16,958 |
| 17,352 | 20,507 | 16,966 | 39,113 | |
| 255 | 255 | 255 | 383 | |
| 25.1% | 15.4% | 27.3% | 4.5% | |
| 23.7% | 14.6% | 28.7% | 4.6% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 4,572 | 3,848 | 6,734 | 3,683 | |
| 2,859 | 519 | 3,168 | 2,199 | |
| 1,713 | 3,329 | 3,566 | 1,484 | |
| Dividends paid | 2,037 | – | – | – |
| – | – | – | – | |
| – | 20 | 216 | -38 |
Valuation
- 98.2×
- –
- –
- 4.1×
- 7.8×
- 118.5×
- 41.6×
- 0.8%
- 1.0%
- –
Profitability
- 70.8%
- 10.6%
- 7.9%
- –
- 4.2%
- 17.2%
- –
- –
- –
- –
Growth
- +19.4%
- −33.8%
- –
- –
- +14.6%
Financial health
- 0.8×
- 0.10
- –
- 6.6×
- 2.83
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 46%of 946
Top 46%of 871
Bottom 9%of 563
Top 30%of 867
Bottom 47%of 986
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
46No pass
Philip Fisher
43No pass
Peter Lynch
43No pass
Joel Greenblatt
3No pass
Charlie Munger
45No pass
Terry Smith
43No pass
Questions about Cohance Lifesciences
Is Cohance Lifesciences a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cohance Lifesciences AI analysis
What does Cohance Lifesciences do?
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Hyderabad, India.
Is Cohance Lifesciences stock halal?
Yes. Cohance Lifesciences passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Cohance Lifesciences stock done over the past year?
Down 14.6% over the past twelve months, to ₹459.80. It traded between ₹279.75 and ₹539.95 and is 14.8% below its high.
Who are Cohance Lifesciences's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Cohance Lifesciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.